DK1401492T3 - LTB4 som vaccineadjuvans - Google Patents
LTB4 som vaccineadjuvansInfo
- Publication number
- DK1401492T3 DK1401492T3 DK02737698T DK02737698T DK1401492T3 DK 1401492 T3 DK1401492 T3 DK 1401492T3 DK 02737698 T DK02737698 T DK 02737698T DK 02737698 T DK02737698 T DK 02737698T DK 1401492 T3 DK1401492 T3 DK 1401492T3
- Authority
- DK
- Denmark
- Prior art keywords
- ltb4
- vaccine adjuvant
- vaccine
- enhancing
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Vending Machines For Individual Products (AREA)
- Amplifiers (AREA)
- Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30270501P | 2001-07-05 | 2001-07-05 | |
PCT/CA2002/000955 WO2003004054A1 (en) | 2001-07-05 | 2002-06-26 | Ltb4 as vaccine aduvant |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1401492T3 true DK1401492T3 (da) | 2009-09-14 |
Family
ID=23168877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02737698T DK1401492T3 (da) | 2001-07-05 | 2002-06-26 | LTB4 som vaccineadjuvans |
Country Status (8)
Country | Link |
---|---|
US (1) | US7914800B2 (de) |
EP (1) | EP1401492B1 (de) |
AT (1) | ATE431745T1 (de) |
CA (1) | CA2452008C (de) |
DE (1) | DE60232413D1 (de) |
DK (1) | DK1401492T3 (de) |
ES (1) | ES2329118T3 (de) |
WO (1) | WO2003004054A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473708B2 (en) | 1996-02-15 | 2009-01-06 | Jean Gosselin | Agents with leukotriene B4-like antiviral (enveloped RNA) activities |
US20050239889A1 (en) * | 2004-04-26 | 2005-10-27 | Jean Gosselin | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration |
ATE474603T1 (de) | 2004-09-20 | 2010-08-15 | Ltb4 Sweden Ab | Stabilisiertes leukotrien b4 (ltb4) pharmazeutikum |
WO2012000082A1 (en) * | 2010-06-29 | 2012-01-05 | UNIVERSITé LAVAL | Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-l-like receptor ligand or a nod-like receptor ligand to enhance the innate immune response |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789441A (en) * | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
-
2002
- 2002-06-26 EP EP02737698A patent/EP1401492B1/de not_active Expired - Lifetime
- 2002-06-26 US US10/482,393 patent/US7914800B2/en not_active Expired - Fee Related
- 2002-06-26 DE DE60232413T patent/DE60232413D1/de not_active Expired - Lifetime
- 2002-06-26 ES ES02737698T patent/ES2329118T3/es not_active Expired - Lifetime
- 2002-06-26 WO PCT/CA2002/000955 patent/WO2003004054A1/en not_active Application Discontinuation
- 2002-06-26 CA CA2452008A patent/CA2452008C/en not_active Expired - Fee Related
- 2002-06-26 AT AT02737698T patent/ATE431745T1/de not_active IP Right Cessation
- 2002-06-26 DK DK02737698T patent/DK1401492T3/da active
Also Published As
Publication number | Publication date |
---|---|
EP1401492B1 (de) | 2009-05-20 |
ES2329118T3 (es) | 2009-11-23 |
CA2452008C (en) | 2012-03-06 |
CA2452008A1 (en) | 2003-01-16 |
EP1401492A1 (de) | 2004-03-31 |
US20040208882A1 (en) | 2004-10-21 |
US7914800B2 (en) | 2011-03-29 |
DE60232413D1 (en) | 2009-07-02 |
ATE431745T1 (de) | 2009-06-15 |
WO2003004054A1 (en) | 2003-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
EP1504112A4 (de) | Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
DK1113816T3 (da) | Influenzavirus-vaccinesammensætning | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
DE60210456D1 (de) | Solubisierung von kapseln polysacchariden | |
CY2013036I1 (el) | Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
MA29406B1 (fr) | Vaccin toxoide alpha de c. perfringens | |
ATE309821T1 (de) | Influenzavirus-impfstoffzusammensetzung | |
WO2006126981A3 (en) | Compositions and methods for mucosal vaccination | |
GB2386072A (en) | Novel vaccine | |
ATE521621T1 (de) | Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans | |
NO20023935D0 (no) | Ny, ikke-antigen, mucosal adjuvantformulering som modulerer effektene av substanser, inkludert vaksineantigener, i kontakt medmucosale kroppsoverflater | |
DE60015084D1 (de) | Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
GB2444676A (en) | Adjuvanted vaccine | |
DK1395283T3 (da) | Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine | |
WO2003039592A3 (de) | Zelluläre impfstoffe mit adjuvanzien | |
DK1401492T3 (da) | LTB4 som vaccineadjuvans | |
NO20024255L (no) | HIV-immun adjuvansterapi | |
WO2005123112A3 (en) | Method of enhancing the immune response to a vaccine | |
SG147465A1 (en) | Vaccine | |
HU0102823D0 (en) | A broad spectrum infectious bursal disease virus vaccine | |
AR026913A1 (es) | Analogos de (1s-cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales |